Share This Link

Cyclosporine blocks the activation of T cells by inhibiting the enzyme calcineurin, which is required for the transcription of interleukin-2¹². Interleukin-2 is a cytokine that stimulates the proliferation and differentiation of T cells, which are responsible for recognizing and attacking foreign antigens on the donor organ. By blocking interleukin-2 production, cyclosporine prevents the activation and expansion of T cells, and thus reduces the immune response to the transplanted organ¹³.

Option C is incorrect because cyclosporine does not interfere with the synthesis of nucleic acids, which are essential for the replication and function of immune cells. Cyclosporine does not directly affect DNA or RNA synthesis or function, but rather modulates gene expression through its interaction with cyclophilin and calcineurin. Cyclosporine may have some anti-cancer effects by inducing apoptosis or inhibiting angiogenesis in some malignant cells, but this is not its primary mechanism of action¹².

Option D is incorrect because cyclosporine does not bind to specific antigens or receptors on the surface of immune cells and either neutralize them or induce their destruction. Cyclosporine acts intracellularly by binding to cyclophilin and inhibiting calcineurin, which are both involved in signal transduction pathways that regulate T cell activation. Cyclosporine does not directly bind to or affect the antigen recognition or receptor-mediated signaling of immune cells¹².

Option A is incorrect because daclizumab does not decrease the frequency and severity of diarrhea, abdominal pain, and rectal bleeding. These are symptoms of ulcerative colitis, a chronic inflammatory bowel disease that affects the colon and rectum. Daclizumab may be used to treat ulcerative colitis by reducing the inflammation and immune-mediated damage to the intestinal mucosa , but this is not its effect in leukemia.

Option B is incorrect because daclizumab does not increase appetite, weight gain, energy level, and quality of life. These are general indicators of health and well-being that may be affected by various factors such as nutrition, physical activity, mental health, social support, and environmental conditions. Daclizumab may improve some aspects of quality of life for patients with leukemia by reducing symptoms and complications of the disease¹³, but this is not a specific outcome of its therapy.

Option C is incorrect because daclizumab does not normalize stool culture, blood count, electrolytes, and liver function tests. These are laboratory tests that measure different aspects of the body's function and health status. Daclizumab may affect some of these tests by causing side effects such as infection, bone marrow suppression, hepatotoxicity, or electrolyte imbalances¹², but this is not an indication of its effectiveness.